GA, a common drug for the treatment of MS, has been shown to induce type II activation of monocytes as indicated by a shift in the IL-10/IL-12 profile and an ability to bias T cell responses towards Th2 in vivo [18]. The gene discussed is IL10; the disease is myeloid sarcoma.